Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

Inclusion Criteria:

Pathologic or cytologic diagnosis of solid tumors or lymphoma

Metastatic disease

No curative or effective therapy exists
Measurable or nonmeasurable disease

No clinically relevant third-space fluid collections

Fluid collections must be drained before study enrollment
No leukemia
No CNS metastases

Exclusion Criteria:

ECOG performance status 0-2
Life expectancy ≥ 12 weeks
ANC ≥ 1,500/mm^3
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9 g/dL
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST and ALT ≤ 3.0 times ULN (5 times ULN if liver has tumor involvement)
Creatinine clearance ≥ 45 mL/min
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after completion of study therapy
No active infection or other serious illness that would preclude study participation
No weight loss ≥ 10% within the past 6 weeks
No peripheral neuropathy (e.g., diabetic neuropathy) ≥ CTC grade 1
Must be able to take concurrent vitamin B12 and folic acid

PRIOR CONCURRENT THERAPY:

No more than 1 prior chemotherapy regimen for metastatic disease
More than 12 months since prior adjuvant therapy
More than 30 days since prior drug that has not received regulatory approval
More than 30 days since prior radiation therapy and recovered (alopecia allowed)
Prior standard postoperative adjuvant radiation therapy for rectal cancer allowed
No prior radiation therapy to ≥ 25% of bone marrow
No prior oxaliplatin or pemetrexed disodium
No NSAIDs or acetylsalicylic acid 2 days before (5 days for long-acting agents [e.g., piroxicam]), during, and for 2 days after each dose of pemetrexed disodium
No concurrent nonpalliative radiation therapy or surgery for cancer
No concurrent hormonal cancer therapy (except medroxyprogesterone)
No other concurrent experimental medications (except thymidine)
No other concurrent chemotherapy or immunotherapy
No other concurrent anticancer therapy
Concurrent palliative radiation therapy allowed for small areas of painful metastasis that cannot be managed adequately by systemic or local analgesics